Protein / target
Dipeptidyl peptidase 4
Protein at a glance
Biological role
Serine-type endopeptidase
Strongest disease association
Intelligence
Therapeutic position
Established drug target
Research activity
Emerging research
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation.
View complete UniProt function annotationHide complete annotation
Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation (PubMed:10900005, PubMed:10951221, PubMed:11772392, PubMed:17287217). Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC (PubMed:10900005, PubMed:10951221, PubMed:11772392, PubMed:14691230). Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner (PubMed:17287217). Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion (PubMed:11772392). In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM (PubMed:10593948, PubMed:16651416). May be involved in the promotion of lymphatic endothelial cells adhesion, migration and tube formation (PubMed:18708048). When overexpressed, enhanced cell proliferation, a process inhibited by GPC3 (PubMed:17549790). Also acts as a serine exopeptidase with a dipeptidyl peptidase activity that regulates various physiological processes by cleaving peptides in the circulation, including many chemokines, mitogenic growth factors, neuropeptides and peptide hormones such as brain natriuretic peptide 32 (PubMed:10570924, PubMed:16254193). Removes N-terminal dipeptides sequentially from polypeptides having unsubstituted N-termini provided that the penultimate residue is proline (PubMed:10593948)
Subcellular location
Domains and Gene Ontology detail (39)Hide
Gene Ontology
- Capical plasma membrane
- Ccell surface
- Cendocytic vesicle
- Cextracellular exosome
- Cextracellular region
- Cfocal adhesion
- Cintercellular canaliculus
- Clamellipodium
- Clamellipodium membrane
- Clysosomal membrane
- Cmembrane
- Cmembrane raft
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell migration
- ·endothelial cell migration
- ·negative regulation of neutrophil chemotaxis
Cell proliferation & survival
- ·positive regulation of cell population proliferation
Cell adhesion
- ·Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-…
- ·Cell junction
- ·cell adhesion
- ·negative regulation of extracellular matrix disassembly
Proteolysis
- ·Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-…
- ·aminopeptidase activity
- ·dipeptidyl-peptidase activity
- ·protease binding
Immune signalling
- ·T cell activation
- ·T cell costimulation
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
15 medicines meet Open Targets' target-level approved-medicine definition; the 3 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Dipeptidyl peptidase IV inhibitor
Indicated for Diabetes Mellitus, Type 2, Hyperlipidemias, Myocardial Infarction, Stroke
Dipeptidyl peptidase IV inhibitor
Indicated for Diabetes Mellitus, Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibitor
Indicated for Diabetes Mellitus, Diabetes Mellitus, Type 2
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene DPP4
Gene-level evidence surfaced through the gene DPP4that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
21 compounds recorded · 15 approved · 6 in clinical development
View all recorded compounds (10)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Strong
Protein degraders — Emerging
View underlying tractability evidence (11)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Label change
Label change: EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE (NDA212614)
- Label change
Label change: LINAGLIPTIN AND METFORMIN HYDROCHLORIDE (NDA201281)
- Label change
Label change: LINAGLIPTIN AND METFORMIN HYDROCHLORIDE (NDA208026)
- Label change
Label change: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (NDA022044)
- Label change
Label change: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (NDA202270)
- Label change
Label change: EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE (NDA212614)
- New publicationDPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease.
- Indication expanded
Indication expansion: LINAGLIPTIN AND METFORMIN HYDROCHLORIDE (NDA201281)
- Indication expanded
Indication expansion: LINAGLIPTIN AND METFORMIN HYDROCHLORIDE (NDA208026)
- New publicationEffect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study.
- New publicationDipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes.
- New publicationDose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.
Research activity
Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.
Most cited
Recent
Europe PMC papers linked directly to this protein.